

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILIT	NG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/522,554 03/10/2000		10/2000	Francis M. Rossi	16650016US01	5524
27194	7590	10/07/2002			
	IMON AI	RNOLD & WH	EXAMINER		
BOX 34 301 RAVENS			CEPERLEY, MARY		
MENLO PAR	.K, CA 94	1025		ART UNIT	PAPER NUMBER
				1641	11
			DATE MAILED: 10/07/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)				
Advisory Action	09/522,554	ROSSI, FRANCIS M.				
navioury motion	Examiner	Art Unit				
	Mary (Molly) E. Ceperley	1641				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 16 September 2002 FAILS TO PLACE Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment which	ition. A proper reply to a places the application in				
PERIOD FOR RE	PLY [check either a) or b)]					
a) The period for reply expires 4 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period o fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of t (2) as set forth in (b) above, if checked. Any reply received by the Offic timely filed, may reduce any earned patent term adjustment. See 37 C	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CFI f extension and the corresponding amount of the shortened statutory period for reply one later than three months after the mail	g date of the final rejection. IE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension on the fee. The appropriate extension originally set in the final Office action; or				
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR	Brief must be filed within the pe	riod set forth in f the appeal.				
2. The proposed amendment(s) will not be entered because:						
(a) 🛛 they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) ☐ they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application ir issues for appeal; and/or	n better form for appeal by mater	rially reducing or simplifying the				
(d) They present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: <u>See the attached letter.</u> .						
3. Applicant's reply has overcome the following rejection	on(s):					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed amendment				
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: See	reconsideration has been consideration has been consideration has been consideration.	dered but does NOT place the				
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly				
7. For purposes of Appeal, the proposed amendment (explanation of how the new or amended claims wo	(s) a)⊠ will not be entered or b) uld be rejected is provided belov	☐ will be entered and an wor appended.				
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected: <u>13-20</u> .						
Claim(s) withdrawn from consideration:						
☐ The proposed drawing correction filed on is a)☐ approved or b)☐ disapproved by the Examiner.						
☐ Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10.⊠ Other: <u>PTO-1449 filed 12 March 2002</u>						
		Mary (Molly) E. Ceperley Primary Examiner Art Unit: 1641				

Application/Control Number: 09/522,554

Art Unit: 1641

1) The amendment filed 15 September 2002 under 37 CFR 1.116 in reply to the final rejection has been considered but is not deemed to place the application in condition for allowance and will not be entered because:

- --The proposed amendment is not deemed to place the application in better form for appeal by materially simplifying the issues for appeal.
- --There is no convincing showing under 37 CFR 1.116(b) why the proposed amendment is necessary and was not earlier presented.
- --The proposed amendment raises new issues that would require further consideration.
- 2) Applicants have not provided any reason for why the proposed narrowing of the claims to define the "affinity anchor molecule" as "an oligonucleotide" was necessary and was not earlier presented. Applicants have also not discussed how this limitation would further define the claimed invention over the prior art of record.
- "porous matrix overlays" the "electrode" rather than the "electrode array device" (see the paragraph directly below), is supported at page 6, lines 33-34 of the specification. However, the rejection of paragraph 4)a) of the final rejection is still maintained for the reason that claim 13 is drawn to a "microarray device" comprising (a) "an electrode array device" and (b) "a plurality of molecules of interest" but the claim fails to specify the spatial and/or functional relationship of components (a) and (b) to each other. It is further noted that there is no requirement in claim 13 that the "affinity anchor molecules" be electrochemically immobilized on the "electrode array" (specification, page 11, lines 15 and 16); the "affinity anchor molecules" must only be "located within the porous matrix" (i.e. they may be simply dispersed within the matrix prior to the matrix being coated on the "electrode array device").

Application/Control Number: 09/522,554

Art Unit: 1641

4) The proposed amendment to claim 13 is confusing for the reason that it is unclear how the "porous matrix overlays the electrode array device" when the "electrode array device" itself is composed of "electrode cells", "a porous matrix", and "a plurality of affinity anchor molecules".

5) The request for reconsideration has been considered but does not overcome the prior art rejections of record. The following comments are provided in response to applicants' arguments filed in the response of 16 September 2002.

Applicants argue that Montgomery is not pertinent to the claimed invention for the reason that it is directed to an *in situ* electrochemical synthesis process to synthesize oligomers attached to an electrode and does not describe the instantly claimed hybridization of claim 17. While Montgomery discloses the positioning of oligonucleotides on an electrode, Montgomery also discloses the use of these immobilized oligonucleotides in a conventional hybridization, as claimed (see col. 25, lines 1-3). Steps (b)-(d) of instant claim 17 are directed to this conventional hybridization method as described by Montgomery. Step (a) of instant claim 17, "electrochemically synthesizing a plurality of different affinity anchor molecules at known location", is inclusive of the method described by Montgomery.

Applicants' argument that Hafeman et al does not disclose or suggest any portion of claim 13 is unconvincing. Applicants' statement that the "photoresponsive electrode" of Hafeman et al differs from the "electrochemistry system" of the instant invention does not take in to account the actual language and required components of instant claim 13. This claim does not recite an "electrochemistry system" but rather "an electrode array device" comprised of "electrode cells", a "porous matrix" and "affinity anchor molecules" defined as "oligonucleotides". Contrary to applicants' statement, this same combination of components is described by the reference. See Hafeman et al: the "electrode" of col. 2, line 31-43 containing multiple "sites"; the "porous film" on this surface described at col. 4, lines 20-30; bound nucleic acid sequences (oligonucleotides) on the device as described at col. 14, lines 46-61.

Application/Control Number: 09/522,554

Art Unit: 1641

Page 4

6) Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. (Molly) Ceperley whose telephone number is (703) 308-4239. The examiner can normally be reached from 8 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, can be reached at (703) 305-3399. The fax phone number for responses to be filed BEFORE final rejection is (703) 872-9306. The fax phone number for responses to be filed AFTER final rejection is (703) 872-9307.

Questions which are NOT RELATED TO THE EXAMINATION ON THE MERITS, should be directed to TC 1600 CUSTOMER SERVICE at (703) 308-0198. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

October 3, 2002

Mary E. Ceperley Mary E. (Molly) Ceperley **Primary Examiner**

Art Unit 1641